Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug;31(4):14-34.
doi: 10.21315/mjms2024.31.4.2. Epub 2024 Aug 27.

Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis

Abdul Matin  1   2 , Gul-E-Saba Chaudhry  1 , Mohamad Nor Azra  1 , Mohamad Gazali  1   3 , Yik Sung Yeong  1 , Tengku Sifzizul Tengku Muhammad  1
Affiliations
Review

Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis

Abdul Matin et al. Malays J Med Sci. 2024 Aug.

Abstract

Atherosclerosis is characterised by the accumulation of fatty deposits and plaque as a result of a continuously high level of low-density lipoprotein cholesterol (LDL-C) in the blood. The primary objective of this research is to assess the current status of knowledge, research endeavours and developmental trajectories about proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in correlation with atherosclerosis treatment. Additionally, this study aims to compile bibliometric and scientometric investigations within this domain through rigorous scientometric analysis. Analysing the bibliometric landscape and global research trends associated with PCSK9 inhibitors can contribute valuable insights into comprehending atherosclerosis. This is exemplified by examining publications within the Web of Science Core Collection (WOSCC) database from 2008 to 2022. Citespace was used for frequency, co-occurrence, co-citation, grouping and burst analysis, and Microsoft Excel was used to manage descriptive datasets. Eight hundred eighty-five publications available from WOSCC database between the years 2008 and 2022 were extracted and examined. Over the period, 3,138 collaborating institutions from 87 countries, a staggering 7,750 writers involved and 325 distinct journals published about PCSK9 inhibitors studies. Among authors, Sabatine et al. and the journal The New England Journal of Medicine has had the most significant impact. Lipid-lowering therapy and bempedoic acid are the most prominent topical clusters associated with PCSK9 inhibitors, and the most often used keywords are efficacy, safety and PCSK9 inhibitors. We believe this is the first comprehensive analysis of PCSK9 inhibitors research and publications conducted using Scientometric. These results demonstrate the nascence of PCSK9 inhibitors research. They may encourage a wide range of stakeholders, particularly early career researchers from various disciplines, to work together in the future.

Keywords: PCSK9; PCSK9 inhibitors; atherosclerosis; bempedoic acid; lipid-lowering therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None.

Figures

Figure 1
Figure 1
The present study’s flowchart or methodological framework on PCSK9 inhibitors
Figure 2
Figure 2
Publication trends of PCSK9 inhibitors search between 2008 and 2022, with 2016–2022, the number of documents shot up quickly
Figure 3
Figure 3
Regarding regional and state distribution of PCSK9 inhibitors researches worldwide, darker shades of green indicate more overall publications, while lighter ones indicate fewer publications
Figure 4
Figure 4
Number of publications issued between 2008 and 2022 from the topmost 10 countries
Figure 5
Figure 5
Level of open access to the PCSK9 inhibitors-related literature written between 2008 and 2022, based on the WOSCC database
Figure 6
Figure 6
An author co-citation analysis
Figure 7
Figure 7
The knowledge maps for journal co-citation analysis
Figure 8
Figure 8
An overlay of the cited journal in PCSK9 inhibitors research
Figure 9
Figure 9
Network of country/region co-citation analysis
Figure 10
Figure 10
Network of institutions co-citation analysis
Figure 11
Figure 11
Network of study area co-citation analysis
Figure 12
Figure 12
A document co-citation analysis
Figure 13
Figure 13
Summary of identified document cluster lifetimes in PCSK9 inhibitors research from 2008 to 2022 generated from the CiteSpace
Figure 14
Figure 14
Keyword distribution, created by Bjorn’s Word Cloud by Microsoft Excel 2022 computer worksheet software
See this image and copyright information in PMC

References

    1. Violi F, Nocella C, Loffredo L, Carnevale R, Pignatelli P. Interventional study with vitamin E in cardiovascular disease and meta-analysis. Free Radic Biol Med. 2022;178(November 2021):26–41. doi: 10.1016/j.freeradbiomed.2021.11.027. - DOI - PubMed
    1. Dyck GJB, Raj P, Zieroth S, Dyck JRB, Ezekowitz JA. The effects of resveratrol in patients with cardiovascular disease and heart failure: a narrative review. Int J Mol Sci. 2019;20(4):1–28. doi: 10.3390/ijms20040904. - DOI - PMC - PubMed
    1. Amput P, McSweeney C, Palee S, Phrommintikul A, Chattipakorn SC, Chattipakorn N. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function. Biomed Pharmacother. 2019;109(October 2018):1171–1180. doi: 10.1016/j.biopha.2018.10.138. - DOI - PubMed
    1. Satyanarayana, Chakrapani . Biochemistry. 4th ed. A division of Reed Elsevier India Private Limited: Elsevier; 2013.
    1. Mohamad H, Razak MFA, Kamaruddin NN, Din LHM, Asari A, Andriani Y, et al. PCSK9 inhibitory activity of marine-derived compounds, aaptaminoids, and benzamide originated from Aaptos aaptos and Acanthaster planci as a potential treatment for atherosclerosis. J Appl Pharm Sci. 2020;10(8):111–123. doi: 10.7324/JAPS.2020.10813. - DOI

LinkOut - more resources